BPU17
BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs) . BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent[1].
Product Specifications
CAS Number
2198977-68-1
UNSPSC
12352211
Target
Mitochondrial Metabolism
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/bpu17.html
Purity
98.16
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
ClC1=CC=C(NC(NC(C2CCC2)=O)=O)C=C1
Molecular Formula
C12H13ClN2O2
Molecular Weight
252.70
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD45RA (PTPRC/818), CF405S conjugate, 0.1mg/mL
MUC16 / CA125 (Ovarian Carcinoma Marker) (OCA125/2349R), CF647 conjugate, 0.1mg/mL
TACSTD2 / TROP2 (Epithelial Marker) (TACSTD2/2151), CF405S conjugate, 0.1mg/mL
